BioWorld Asia

Jan. 7, 2009

Genmab Shares Slide on Interim Zalutumumab Data

Shares in Genmab A/S were off by more than 7 percent during trading Tuesday following an interim update on a Phase III pivotal study of zalutumumab (HuMax-EGFr) in head and neck cancer. (BioWorld International) Read More

UK/U.S. Program Mapping Chemo Response to Cancers

Hair Loss Gene has Serendipitous Message for Genetic Sleuths

UK's Stem Cell Proponents Meeting to Discuss Future

Small EU Biofirms Benefit from Special Assistance

Cytos Shares Surge on Pfizer Deal Commitment

Cellectis Terminates genOway's Homologous Recombination Deal

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 24, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Illustration of tau accumulating in a neuron cell.

ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

BioWorld

ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...